|
|
|
16.06.26 - 16:06
|
Pegasus Tech Ventures and CYBERDYNE Launch 10 Billion Japanese Yen Corporate Venture Capital Fund to Accelerate “HCPS Cybernics with Physical AI” (Business Wire)
|
|
|
SAN JOSE, Calif.--(BUSINESS WIRE)--$TYO #CVC--Pegasus Tech Ventures, a Silicon Valley–based global venture capital firm and leading provider of Venture Capital-as-a-Service (VCaaS) solutions, today announced the launch of a JPY 10 billion (US $60M) Corporate Venture Capital (CVC) fund in partnership with CYBERDYNE, Inc., a leading company in the field of Cybernics that fuses bio/medical systems with AI-robotics and information technologies.
Pegasus Tech Ventures will serve as the General Partner of the fund, and CYBERDYNE will participate as the sole Limited Partner. Through Pegasus' VCaaS platform, CYBERDYNE will gain access to Silicon Valley and leading innovation ecosystems around the world. Leveraging Pegasus' global network of startups, investors, and corporate partners, the collaboration is designed to accelerate strategic investments, technology partnerships, and new business opportunities in emerging sectors.
The fund will invest in startups developing technologies across robotics, Physical AI...
|
|
|
16.06.26 - 13:33
|
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer′s Disease (GlobeNewswire EN)
|
|
|
NEWTON, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced the nomination of two development candidates in its Enhanced Brain Delivery (EBD) program as treatments for AD. Building on robust preclinical data from both in vitro and in vivo studies, the Company has exercised its option with JCR Pharmaceuticals (JCR) as part of its previously signed agreement and will advance both candidates combining Acumen's AβO-selective antibody expertise and JCR's validated transferrin-receptor-targeting blood-brain barrier-penetrating technology, termed J-Brain Cargo®. By selecting these two candidates, the Company is expanding its optionality by nominating a bispecific antibody derived from sabirnetug as well as one based on a novel, next generation AβO-selective antibo...
|
|
|
|
|
16.06.26 - 07:36
|
Treasures of Olympus 1000 Slot Review (Cision)
|
|
|
Title: Treasures of Olympus 1000
· Release Date: 9 January 2026
· Provider: KingMidas Games (https://kingmidasgames.com/)
· RTP: 96.95%
· Volatility: High
· Hit Rate: 27.94%
· Maximum Win: 15,000x Stake
· Grid Size: 6x5
Treasures of Olympus 1000 Reviewed by the iGaming News Team
The iGaming News team has meticulously reviewed Treasures of Olympus 1000, a mythology-inspired online slot from KingMidas Games that combines colourful visuals, tumbling wins, powerful multipliers and an engaging free spins feature.
Drawing inspiration from the legendary world of Greek...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.06.26 - 08:39
|
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche....
|
|
|
|
|
|
|
09.06.26 - 09:06
|
3D Investment Partners: Leading Proxy Advisory Firm Glass Lewis Recommends Toho Holdings Shareholders Vote “AGAINST” the Proposed Poison Pill (Business Wire)
|
|
|
Highlights “substantial governance concerns” with Toho HD's disproportionate response
Concludes that the Poison Pill may not be in shareholders' best interestsTOKYO--(BUSINESS WIRE)--3D Investment Partners Pte. Ltd., who provides discretionary investment management services to an investment fund which is a shareholder of Toho Holdings Co., Ltd. (TSE: 8129, "Toho HD" or “the Company”) (“3D” or “we”), announced that Glass, Lewis & Co. (“Glass Lewis”), a leading independent provider of proxy research and voting recommendations for the institutional investor community, has recommended that shareholders of Toho HD vote AGAINST Proposal 4 (Gratis allotment of stock acquisition rights — the “Poison Pill Proposal”) at the Company's 78th Annual General Meeting of Shareholders (the “AGM”), scheduled to be held on June 26, 2026.
In its report, Glass Lewis determined that the Poison Pill “raises substantial governance concerns” and “may not appear to be in shareholde...
|
|
|
|
|
|
|
|
|
|
|
02.06.26 - 01:06
|
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting (Business Wire)
|
|
|
ONO-4578, an EP4 antagonist, in combination with OPDIVO® and chemotherapy demonstrated a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to the placebo combination group (median PFS, 9.0 months vs. 6.9 months, respectively).
In the subgroup population with PD-L1 CPS ≥1, median PFS in the ONO-4578 combination group was 9.9 months, showing a marked clinical benefit compared to 5.7 months in the placebo combination group.
Based on these promising results, preparations are underway to initiate a phase 3 clinical study.
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced the results of the phase 2 clinical study (ONO-4578-08 study) of the EP4 antagonist ONO-4578 in patients with previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer (including gastroesophageal junction cancer). The results were presented at the American Soc...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
